Resona Asset Management Co. Ltd. Increases Position in Stryker Corporation $SYK

Resona Asset Management Co. Ltd. lifted its position in shares of Stryker Corporation (NYSE:SYK) by 2.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,075 shares of the medical technology company’s stock after purchasing an additional 2,482 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Stryker were worth $34,478,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of SYK. Czech National Bank grew its position in shares of Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after buying an additional 3,366 shares during the last quarter. Kepler Cheuvreux Suisse SA purchased a new stake in Stryker in the third quarter valued at $27,952,000. Daymark Wealth Partners LLC boosted its stake in Stryker by 436.0% in the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after acquiring an additional 37,307 shares in the last quarter. Varma Mutual Pension Insurance Co boosted its stake in Stryker by 10.5% in the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after acquiring an additional 5,100 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC grew its holdings in shares of Stryker by 265.2% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock worth $3,278,000 after purchasing an additional 6,774 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 0.8%

SYK opened at $327.17 on Thursday. The business has a 50 day moving average price of $309.71 and a two-hundred day moving average price of $338.22. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market cap of $125.42 billion, a PE ratio of 37.87, a P/E/G ratio of 2.11 and a beta of 0.77. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

SYK has been the subject of several research reports. Wells Fargo & Company reduced their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. Barclays reduced their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research report on Friday, May 1st. Finally, Evercore set a $350.00 price target on shares of Stryker in a research report on Monday. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $393.91.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.